Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis

References

• José RJ, Brown JS. Bronchiectasis. Br J Hosp Med. 2014;75:C146-C151.
   Web of Science ®Google Scholar
• Cole PJ. Inflammation: a two-edged sword–the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.
   PubMedGoogle Scholar
• Boyton RJ. Bronchiectasis. Medicine (Baltimore). 2012;40:267–272.
   Google Scholar
• Pasteur MC, Bilton D, Hill AT, et al. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–58.
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491–499. Long-term use of nebulised gentamicin in bronchiectasis.
   PubMed Web of Science ®Google Scholar
• Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: A systematic review. Eur Respir J. 2014;44:382–393.
   PubMed Web of Science ®Google Scholar
• Fan L, Lu H, Wei P, et al. Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2015;15:160.
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–667.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose. erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–1267.
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–1259.
   PubMed Web of Science ®Google Scholar
• Katzung BG, Masters SB, Trevor AJ. Basic & clinical pharmacology. Lange Med Book. 13th ed. 2012.
   Google Scholar
• Justo JA, Danziger LH, Gotfried MH. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2013;7:272–287.
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61:377–392.
   PubMed Web of Science ®Google Scholar
• Bruinenberg P, Serisier D, Cipolla D, et al. Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers (HV) and non-cystic fibrosis bronchiectasis (BE) patients. J Cyst Fibros [Internet]. 2011;10:S29.
   PubMed Web of Science ®Google Scholar
• Weers J, Tarara T. The PulmoSphereTM platform for pulmonary drug delivery. Ther Deliv. 2014;5:277–295.
   PubMedGoogle Scholar
• Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: A phase I, randomized, dose-escalation study. Clin Ther. 2013;35:1571–1581.
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study. Eur Respir J. 2013;41:1107–1115.
   PubMed Web of Science ®Google Scholar
• De Soyza A, Aksamit T, Operschall E, et al. Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB). Eur Respir Journal Conf Eur Respir Soc Annu Congr. 2015; 46 (suppl 59) PA2617
   Google Scholar
• Weers J. Inhaled antimicrobial therapy - Barriers to effective treatment. Adv Drug Deliv Rev. 2015;85:24–43.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics. 2016;8:1–31.
   Web of Science ®Google Scholar
• Cipolla D, Chan H-K. Inhaled antibiotics to treat lung infection. Pharm Pat Anal [Internet]. 2013;2:647–663.
   PubMedGoogle Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812–817.
   PubMed Web of Science ®Google Scholar
• Aradigm Corporation. Aradigm reports successful ORBIT-1 bronchiectasis study with inhaled liposomal ciprofloxacin. Aradigm Corporation. 2011.
   Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975–982.
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738–749.
   PubMed Web of Science ®Google Scholar